Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24628147 | 0.85 | SIGMAR1 (0.58) | SIGMAR1CXCR3HSD11B1SMN1; SMN2MC4R | |
| SCHEMBL25969216 | 0.84 | HSD11B1 (0.56) | CXCR3HSD11B1MEN1ALDH1A1KMT2A | |
| SCHEMBL12864588 | 0.79 | CXCR3 (0.65) | SIGMAR1CXCR3ALDH1A1DRD4CHRM2 | |
| SCHEMBL11152580 | 0.78 | CXCR3 (0.64) | SIGMAR1CXCR3HSD11B1MEN1ALDH1A1 | |
| SCHEMBL18171323 | 0.78 | KDM4E (0.53) | SIGMAR1CXCR3KMT2ASMN1; SMN2MC4R | |
| SCHEMBL9129298 | 0.78 | SIGMAR1 (0.75) | SIGMAR1KMT2AMC4RDRD4LMNA | |
| SCHEMBL576868 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KMT2AMC4RDRD4LMNA | |
| SCHEMBL1041303 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KMT2AMC4RDRD4LMNA | |
| SCHEMBL242970 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KMT2AMC4RDRD4LMNA | |
| SCHEMBL1415730 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KMT2AMC4RDRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2023-08-17 | — | — | US | disclosed |
| US-7884097-B2 | Contains 1-(2-Aminoethyl)piperidine and 2-adamantanone; mycobacterial infections | SEQUELLA, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1670314-A4 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA INC (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1670314-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | Sequella, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | CHAT, DCX, GAP43 | SIGMAR1 4523/4885CXCR3 1590/4885USP2 2579/4885 |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | SIGMAR1 4157/4885CXCR3 1399/4885USP2 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.